Topical combo based on Pfizer and Novartis drugs advances after clearing early clinical testnews2022-01-25T11:46:17+00:00January 25th, 2022|Fierce Pharma|
Novaliq eyes dermatology opportunity, spinning off 3 programs and securing $15M for clinical trialsnews2022-01-25T11:42:17+00:00January 25th, 2022|Fierce Pharma|
J&J extends long-acting injectable biologic pact after Midatech clears early milestonenews2022-01-25T11:39:07+00:00January 25th, 2022|Fierce Pharma|
Bayer leads $80M funding round for Cellino, betting on new cell therapy manufacturing platformnews2022-01-25T05:48:06+00:00January 25th, 2022|Fierce Pharma|
FDA bans Lilly, Regeneron antibody use in COVID-19 patients infected by omicronnews2022-01-24T22:26:22+00:00January 24th, 2022|Fierce Pharma|
Argenx, already deep into its Vyvgart launch, charts course to become immunology ‘powerhouse’: CEOnews2022-01-24T19:11:59+00:00January 24th, 2022|Fierce Pharma|
Gilead pulls 2 cancer accelerated approvals as changing lymphoma landscape disrupts confirmatory trialnews2022-01-24T16:34:27+00:00January 24th, 2022|Fierce Pharma|
On second thought, Oncopeptides decides not to give up on Pepaxto in the U.S., but won’t say whynews2022-01-24T16:28:59+00:00January 24th, 2022|Fierce Pharma|
Pfizer takes a surprising hit to its rare disease plan as FDA snubs new growth deficiency mednews2022-01-24T15:27:38+00:00January 24th, 2022|Fierce Pharma|
With omicron on the prowl, FDA extends inspection pause into Februarynews2022-01-24T15:01:26+00:00January 24th, 2022|Fierce Pharma|
